IP Verse

Methods Of Treating Prostate Cancer

Patent No. EP3490560 (titled "Methods Of Treating Prostate Cancer") was filed by Janssen Pharmaceutica on Jul 28, 2017. The application was issued on Jan 22, 2025.

Patent Summary

Niraparib, a PARP inhibitor, is used to treat prostate cancer in patients with DNA repair anomalies, such as BRCA-1 or BRCA-2 mutations. The treatment is effective in patients with castration-resistant prostate cancer, including those who have failed androgen receptor-targeted therapies. Niraparib's mechanism of action involves inducing DNA damage and inhibiting PARP-mediated repair, leading to tumor cell death. The treatment is administered orally and can be used in combination with androgen deprivation therapy.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HAMM & WITTKOPPOct 21, 2025HAMM & WITTKOPP
TEVA PHARMACEUTICALSOct 21, 2025VON KAUFFMANN
GENERICS UKOct 20, 2025RUSSELL
SANDOZSep 17, 2025ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3490560

JANSSEN PHARMACEUTICA
Application Number
EP17754226A
Filing Date
Jul 28, 2017
Status
Granted And Under Opposition
Dec 20, 2024
Publication Date
Jan 22, 2025
External Links
Slate, Register , Google Patents